Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (545)	7/10/2000 10:32:14 AM
From: John Lacelle	Read Replies (2) \| Respond to of 746

Jim, The main problem I have with what Celera has done is that first, the human genome is a very diverse thing. For example, its long been known that Africans who suffer from sickle cell anemia do so because they have genetic code that gives rise to a different type of hemoglobin. This protein then creates the "sickle" shape and creates the disease. Celera has sequenced only one human and people are making the claim that they can "cure every disease known to man" and other outrageous things. This is just like the snake oil salesmen of yesteryear. It is a big step, no, I would say a gigantic leap to go from having the sequence of a gene and providing a "cure" for the underlying disease. My suggestion is that everyone who is buying into this hype take a look at the insider positions. I think you will find that these insiders are selling their stock and options because they know that the riches from this discovery are decades away but the instant riches from dumping stock are there for the taking, as long as ignorant fools are willing to poor their money into these pipe dreams... -John